Home

Rahul D. Ballal

CIK 1805097 · Chief Executive Officer · last filed 2026-06-23

Rahul D. Ballal is a Chief Executive Officer who has filed 32 SEC Form 4 insider transactions across 2 companies since 2020. The most recent filing, for AGIO, was dated Jun 23, 2026. Across all open-market trades the lifetime net is −$3.7M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $511.7K across reported positions.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$511.7K

Companies

2

Total Filings

32

Lifetime Open-Market Net

-$3.68M

Filer Profile

Reported Address
C/O ENLIVEN THERAPEUTICS, INC.
205 PARK ROAD
BURLINGAME, CA 94010
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
AGIO Director 15,230 $33.60 $511.7K -$1.12M 10 2026-06-23
Enliven Therapeutics, Inc. (IMRA) Delisted Director 32,761 $14.59 $478.0K -$2.56M 16 2026-02-17

Recent Filings

32 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-06-23 AGIO Mixed +2,816 $0 EDGAR
2026-02-17 Enliven Therapeutics, Inc. (IMRA) Delisted Grant (A) — $0 EDGAR
2025-08-13 AGIO Exer (M) +2,302 $0 EDGAR
2025-06-23 AGIO Mixed +2,120 $0 EDGAR
2025-02-10 Enliven Therapeutics, Inc. (IMRA) Delisted Grant (A) — $0 EDGAR
2024-11-12 AGIO Mixed — -$597.3K EDGAR
2024-11-08 AGIO Notice (144) −10,000 -$581.9K EDGAR
2024-11-07 AGIO Notice (144) −10,000 -$535.2K EDGAR
2024-10-10 Enliven Therapeutics, Inc. (IMRA) Delisted Mixed — -$146.6K EDGAR
2024-10-08 ELVN Notice (144) −10,420 -$286.0K EDGAR
Showing 1–10 of 32
Page 1 of 4
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.